concept being pumped, if not at DGI. Hmmmmmmmph.......
Sunesis Announces Appointments of Daniel Swisher to Chief Operating Officer and Steven James to Chief Business Officer
Thursday March 13, 12:00 pm ET
SOUTH SAN FRANCISCO, Calif., March 13 /PRNewswire/ -- Sunesis Pharmaceuticals, Inc. today announced the appointments of Steven James to Chief Business Officer and Daniel Swisher to Chief Operating Officer. Mr. Swisher will assume executive responsibilities for business, financial and legal operations and will report directly to James Young, Ph.D., CEO of Sunesis. He will also continue to serve as the Company's Chief Financial Officer.
ADVERTISEMENT
"Dan's operating experience and insight have been invaluable to Sunesis as we begin to advance our discovery pipeline from the lab into the clinic," commented Dr. Young. "I look forward to working closely with Dan and the rest of the executive team as Sunesis continues its development into a fully integrated, discovery-based pharmaceutical company."
In addition, Steven James, in his new role as Chief Business Officer, will assume broader responsibilities for business and corporate development and new product planning activities. Mr. James was previously the Company's Senior Vice President, Business Development.
"Steve has played a key role at Sunesis since its early days and, in particular, has made major contributions in business development. With the recent completion of our collaboration with Merck to discover novel therapeutics for Alzheimer's disease, we have forged three major partnerships in just nine months," commented Dr. Young. "We look forward to Steve's continued contributions in this expanded role."
Mr. Swisher joined Sunesis in January 2002 as the Company's Chief Business Officer and Chief Financial Officer. Most recently, he was Senior Vice President of Sales & Marketing for ALZA Corporation. Under Mr. Swisher's leadership, ALZA's U.S. operations achieved record sales and profit with a team of more than 1,000 professionals aligned in three therapeutic business units. Mr. Swisher earned his M.B.A. degree from the Stanford Graduate School of Business, and a B.A. degree from Yale University.
Mr. James joined Sunesis in 1999. He has over 15 years of biopharmaceutical experience holding positions in business development, new product planning, and sales and marketing for Eli Lilly & Company, Scios, Landec and Isis Pharmaceuticals. Mr. James earned his M.B.A. degree from the Kellogg School of Northwestern University, and a B.S. degree in biology from Brown University.
Sunesis is a leading discovery-based pharmaceutical company that applies its breakthrough fragment-based technologies to create superior oral therapeutics for the most challenging and important disease targets. Sunesis is building a pipeline of innovative therapeutics addressing major diseases through internal development and selective partnering.
--------------------------------------------------------------------------------
Source: Sunesis Pharmaceuticals, Inc. |
